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Despite reductions over the past 2 decades, childhood mortality remains high in low- and middle-income countries in sub-Saharan 
Africa and South Asia. In these settings, children often die at home, without contact with the health system, and are neither ac-
counted for, nor attributed with a cause of death. In addition, when cause of death determinations occur, they often use nonspecific 
methods. Consequently, findings from models currently utilized to build national and global estimates of causes of death are asso-
ciated with substantial uncertainty. Higher-quality data would enable stakeholders to effectively target interventions for the leading 
causes of childhood mortality, a critical component to achieving the Sustainable Development Goals by eliminating preventable 
perinatal and childhood deaths. The Child Health and Mortality Prevention Surveillance (CHAMPS) Network tracks the causes 
of under-5 mortality and stillbirths at sites in sub-Saharan Africa and South Asia through comprehensive mortality surveillance, 
utilizing minimally invasive tissue sampling (MITS), postmortem laboratory and pathology testing, verbal autopsy, and clinical and 
demographic data. CHAMPS sites have established facility- and community-based mortality notification systems, which aim to 
report potentially eligible deaths, defined as under-5 deaths and stillbirths within a defined catchment area, within 24–36 hours so 
that MITS can be conducted quickly after death. Where MITS has been conducted, a final cause of death is determined by an expert 
review panel. Data on cause of death will be provided to local, national, and global stakeholders to inform strategies to reduce peri-
natal and childhood mortality in sub-Saharan Africa and South Asia.
Keywords.  CHAMPS; child mortality; global health; surveillance.
Despite reductions over the past 2 decades, childhood mortality 
remains high in low- and middle-income countries (LMICs) in 
sub-Saharan Africa and South Asia. Children in these countries 
often die without a documented medical history, so the cause 
of death remains unknown [1]. Many countries with high child 
mortality have weak or nonexistent civil registration systems 
and death certificates are often not requested for stillbirths and 
children <5 years of age [2]. Those deaths that occur outside a 
health facility, especially stillbirths and deaths among neonates, 
who may be buried quickly, are likely to be missed from official 
statistics [3–5]. Even for children who die at a health facility, 
determining cause of death is difficult due to the scarcity of 
diagnostic tools and multiple coexisting illnesses, which often 
leads to an incorrect or nonspecific physician-ascribed cause 
of death [6, 7]. Research conducted in sub-Saharan Africa, the 
United States, and Europe indicates discordant diagnoses be-
tween autopsy findings and clinical diagnoses in as many as half 
of deaths [8, 9].
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/69/Supplem
ent_4/S262/5584386 by guest on 23 O
ctober 2019
Mortality Surveillance Methods in CHAMPS Sites • cid 2019:69 (Suppl 4) • S263
While complete diagnostic autopsies (CDA) are considered 
the most comprehensive method to determine cause of death 
[10], they are rarely conducted in LMICs due to cultural and 
religious acceptability issues as well as resource constraints 
[11–14]. A noninvasive substitute for CDA is the verbal autopsy 
(VA), a postmortem structured interview with individual(s) 
close to the deceased, which is recommended by the World 
Health Organization (WHO) [15–16]. However, VAs are ham-
pered by a lack of objective diagnostic information and substan-
tial recall bias and cannot reliably distinguish between many 
diseases with similar clinical presentations, something common 
to many childhood diseases [10, 17]. VA has particular diffi-
culty in providing useful discriminatory information for deaths 
associated with congenital abnormalities [18], deaths in the 
perinatal period, and stillbirths [10]. VA algorithms for deter-
mining the cause of death are dependent on a priori knowledge 
of causes of death and therefore cannot investigate new causes 
of death. Finally, VAs are less and less useful for determining the 
residual causes of death in settings with decreasing mortality. 
The resulting data have limited value for decision making.
The Child Health and Mortality Prevention Surveillance 
(CHAMPS) Network was established to collect robust, stand-
ardized, longitudinal mortality data in a network of sites with 
the overarching objective of understanding and tracking pre-
ventable causes of childhood death in high mortality areas. 
CHAMPS aims to estimate overall and cause-specific mortality 
rates (stillbirth and under-5) in each site and extrapolate to re-
gions with high child mortality beyond the catchment areas. 
The timely and accurate data generated by this initiative is 
intended to drive interventions to accelerate the reduction of 
childhood death and disability in low-resource settings. Sites 
aim to identify all under-5 deaths and stillbirths within the 
catchment area and conduct CHAMPS procedures, including 
postmortem minimally invasive tissue sampling (MITS) (also 
known as minimally invasive autopsy [MIA]), coupled with 
advanced laboratory techniques. The MITS procedure, a tissue 
and body fluid sampling method, was specifically developed to 
help increase acceptance of postmortem specimen testing in de-
veloping countries [19–22]. The procedure is more rapid, less 
invasive (and therefore, potentially more culturally acceptable), 
and less expensive than the CDA [14, 23–25], yet it generates 
equivalent information for many causes of death [19, 21, 24, 
26–32]. For example, in a sample of stillbirths, the MITS proce-
dure was shown to have substantial overall concordance (83%) 
with CDA cause of death determination. Among a sample of 
neonatal deaths, overall concordance was found to be 68%, with 
higher concordance shown in neonates with infectious diseases 
(85%) and preterm complications (60%) [29]. Additionally, 
overall concordance was found to be 72.7% in a study com-
paring MITS and CDA in fetuses [27]. As findings indicate that 
MITS should be done shortly after death to reduce the chance 
of tissue autolysis and postmortem overgrowth [33], sites have 
set up timely and comprehensive mortality detection systems to 
conduct most MITS within 24 hours of the death.
DESIGN
Site surveillance teams enumerate eligible under-5 deaths and 
stillbirths within the defined populations and approach families 
for consent for CHAMPS procedures (see Figure 1 for complete 
eligibility criteria and data collection categories). For eligible 
deaths notified within the MITS timeframe (within 24–36 hours 
of death or the body has been refrigerated), a MITS is conducted 
and additional data (clinical abstraction and VA) are collected. 
For these deaths (“MITS deaths”), a cause of death is determined 
by a Determination of Cause of Death (DeCoDe) expert panel 
that reviews all available data and seeks consensus to determine 
the most likely chain of causes or events leading to death [34]. For 
eligible deaths without a MITS performed (“non-MITS deaths”), a 
smaller subset of data is collected to allow adjustment and extrap-
olation of cause-specific mortality rates. A death may be enrolled 
in non-MITS if it is not notified within the MITS timeframe (and 
the body has not been refrigerated) or the parents refuse MITS. 
See Figure 2 for a high-level depiction of CHAMPS procedures.
Study Population
The CHAMPS Network consists of 7 sites in sub-Saharan Africa 
and South Asia, each with a geographically defined catchment 
Figure 1. Inclusion and exclusion criteria for minimally invasive tissue sampling 
(MITS) and non-MITS enrollment. aA small proportion of confirmed Child Health 
and Mortality Prevention Surveillance (CHAMPS) eligible deaths (ie, family was 
approached for eligibility screening and confirmed eligibility information) are not 
enrolled in CHAMPS due to parental nonconsent or loss to follow-up. bThe MITS 
timeframe may be extended up to 72 hours after death if body is refrigerated shortly 
after death. cCircumstances may prevent the MITS from being conducted after 
MITS consent has been obtained. In these infrequent cases, data collection aligns 
with non-MITS procedures. dHistology is conducted at the site and at the central 
pathology laboratory located at the US Centers for Disease Control and Prevention. 
Abbreviations: CHAMPS, Child Health and Mortality Prevention Surveillance; HIV, 
human immunodeficiency virus; MITS, minimally invasive tissue sampling; TB, tu-
berculosis; VA, verbal autopsy.
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area: Baliakandi and Faridpur, Bangladesh; Bamako (Djicoroni 
Para and Banconi), Mali; Kersa and Harar, Ethiopia; Makeni 
(Bombali Shebora and Bombali Siari Chiefdoms), Sierra 
Leone; Manhiça, Mozambique; Siaya (Karemo) and Kisumu 
(Manyatta), Kenya; and Soweto and Thembelihle, South Africa 
(Figure 3). Following an application process, these sites were 
selected based on a variety of factors, including history of con-
ducting (or capacity to conduct) surveillance, under-5 mortality 
of >50 deaths per 1000 live births in children aged <5 years at 
the time of site selection (2015), and willingness of the local lead 
investigator to use a common, multisite protocol and to share 
data globally in real time; in addition, there was an intent to 
maximize geographic and ecologic diversity among the selected 
sites. A  key consideration in site selection was the possibility 
for a strong relationship between the site and the local ministry 
of health and/or national public health institute, to ensure that 
data collected contribute to national public health policy and 
actions (Table 1). In addition, 2 sites (the sites in Sierra Leone 
and Ethiopia) were selected because of high child mortality and 
limited history of studies to understand disease burden.
For 12–18 months before initiating CHAMPS activities, each 
site established a social-behavioral sciences (SBS) team to ex-
amine local social, cultural, and religious norms and to engage 
local communities to explain the project aims and methods and 
seek their support. Site SBS teams conduct focus groups, assist 
with rumor identification and mitigation, support families, and 
engage the community through a variety of activities [35, 36].
To monitor demographic trends and calculate mor-
tality rates, most sites conduct surveillance within a health 
and demographic surveillance system (HDSS). An HDSS 
Figure 2. Overview of Child Health and Mortality Prevention Surveillance procedures. Abbreviations: CHAMPS, Child Health and Mortality Prevention Surveillance; 
DeCoDe, Determination of Cause of Death; ID, identifier; MITS, minimally invasive tissue sampling.
Figure 3. Map of Child Health and Mortality Prevention Surveillance sites. Abbreviation: CHAMPS, Child Health and Mortality Prevention Surveillance.
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/69/Supplem
ent_4/S262/5584386 by guest on 23 O
ctober 2019
Mortality Surveillance Methods in CHAMPS Sites • cid 2019:69 (Suppl 4) • S265
Ta
bl
e 
1.
 
Se
le
ct
ed
 S
ite
 C
ha
ra
ct
er
is
tic
s 
of
 C
hi
ld
 H
ea
lth
 a
nd
 M
or
ta
lit
y 
Pr
ev
en
tio
n 
Su
rv
ei
lla
nc
e 
Si
te
s
C
ha
ra
ct
er
is
tic
M
oz
am
bi
qu
e
S
ou
th
 A
fr
ic
a
M
al
i
Ke
ny
a
B
an
gl
ad
es
h
E
th
io
pi
a
S
ie
rr
a 
Le
on
e
C
at
ch
m
en
t 
ar
ea
(s
)
M
an
hi
ça
S
ow
et
o 
(s
el
ec
te
d 
8 
cl
us
te
rs
), 
Th
em
be
lih
le
 
an
d 
su
rr
ou
nd
in
g 
in
-
fo
rm
al
 s
et
tle
m
en
ts
B
am
ak
o 
(D
jic
or
on
i 
Pa
ra
 a
nd
 B
an
co
ni
)
S
ia
ya
 C
ou
nt
y 
(K
ar
em
o)
 a
nd
 
K
is
um
u 
(M
an
-
ya
tt
a)
B
al
ia
ka
nd
i a
nd
 
Fa
rid
pu
r 
(s
el
ec
te
d 
6 
su
bc
lu
st
er
s)
Ke
rs
a 
an
d 
H
ar
ar
M
ak
en
i (
B
om
ba
li 
S
he
bo
ra
 a
nd
 
B
om
ba
li 
S
ia
ri 
ch
ie
fd
om
s)
S
et
tin
g
R
ur
al
U
rb
an
U
rb
an
R
ur
al
 (S
ia
ya
); 
ur
ba
n 
(K
is
um
u)
R
ur
al
 (B
al
ia
ka
nd
i);
 
m
ix
ed
 (F
ar
id
pu
r)
R
ur
al
 (K
er
sa
); 
ur
ba
n 
(H
ar
ar
)
U
rb
an
 a
nd
 ru
ra
l
H
D
S
S
 e
st
ab
lis
hm
en
t 
ye
ar
 
19
96
20
17
 (w
ill
 b
e 
fu
lly
 e
st
ab
-
lis
he
d 
in
 2
01
9)
20
06
20
07
 (S
ia
ya
); 
20
16
 
(K
is
um
u)
20
17
 (B
al
ia
ka
nd
i);
 n
o 
H
D
S
S
 e
st
ab
lis
he
d 
(F
ar
id
pu
r)
20
07
 (K
er
sa
); 
20
12
 (H
ar
ar
)
N
o 
H
D
S
S
 e
st
ab
lis
he
d 
(e
ar
ly
 
pl
an
ni
ng
 p
ha
se
; c
ur
re
nt
ly
 
us
in
g 
ce
ns
us
 d
at
a)
To
ta
l p
op
ul
at
io
n 
un
de
r 
su
rv
ei
lla
nc
e 
(2
01
7)
18
6 
00
0
12
3 
22
5 
(2
01
8 
H
D
S
S
)
87
 1
26
 (D
jic
or
on
i 
Pa
ra
); 
13
9 
68
4 
(B
an
co
ni
) (
20
18
 
H
D
S
S
)
93
 0
00
 (S
ia
ya
); 
72
 0
00
 (K
is
um
u)
21
6 
36
2 
(B
al
ia
ka
nd
i);
 
~
2 
00
0 
00
0 
(F
ar
id
pu
r 
6 
su
bc
lu
st
er
s)
13
1 
43
1 
(K
er
sa
); 
50
 0
00
 
(H
ar
ar
)
16
1 
38
3 
Po
pu
la
tio
n 
de
ns
ity
81
/k
m
2
64
00
/k
m
2
17
 7
09
/k
m
2  
(D
jic
or
on
i 
Pa
ra
); 
22
 4
21
/k
m
2  
(B
an
co
ni
)
35
9/
km
2  
(S
ia
ya
); 
es
t.
 1
0 
00
0/
km
2  
(K
is
um
u)
89
4/
km
2  
(B
al
ia
ka
nd
i);
 
11
14
/k
m
2  
(F
ar
id
pu
r 
6 
su
bc
lu
st
er
s)
37
2/
km
2  
(K
er
sa
); 
12
44
/k
m
2  
(H
ar
ar
)
75
21
/k
m
2 ;
 (M
ak
en
i C
ity
); 
13
9.
6/
km
2  
(B
om
ba
li 
S
he
bo
ra
); 
no
 d
at
a 
fo
r 
B
om
ba
li 
S
ia
ri 
al
on
e
U
nd
er
-5
 p
op
ul
at
io
n 
(2
01
7)
26
 4
25
12
 9
62
 
(2
01
8 
H
D
S
S
)
13
 6
31
 (D
jic
or
on
i 
Pa
ra
); 
24
 4
50
 
(B
an
co
ni
) (
20
18
 
H
D
S
S
)
12
 0
90
 (S
ia
ya
); 
11
 7
00
 (K
is
um
u)
20
 1
80
 (B
al
ia
ka
nd
i);
 
~
18
0 
00
0 
(F
ar
id
pu
r 
6 
su
bc
lu
st
er
s)
15
 7
51
 (K
er
sa
); 
42
83
 (H
ar
ar
)
22
 2
47
G
ov
er
nm
en
t 
st
ak
e-
ho
ld
er
s 
In
st
itu
to
 N
ac
io
na
l D
e 
S
aú
de
 
(N
at
io
na
l I
ns
tit
ut
e 
of
 H
ea
lth
)
M
in
is
tr
y 
ap
po
in
te
d 
C
om
m
itt
ee
 fo
r 
M
or
-
bi
di
ty
 a
nd
 M
or
ta
lit
y 
in
 C
hi
ld
re
n,
 G
au
te
ng
 
D
ep
ar
tm
en
t 
of
 H
ea
lth
 
D
is
tr
ic
t 
H
ea
lth
 Te
am
; 
N
IC
D
M
in
is
tr
y 
of
 H
ea
th
; 
IN
ST
AT
S
ia
ya
 a
nd
 K
is
um
u 
co
un
ty
 d
ep
ar
t-
m
en
ts
 o
f 
he
al
th
; 
M
in
is
tr
y 
of
 H
ea
lth
 
In
st
itu
te
 o
f 
E
pi
de
m
i-
ol
og
y,
 D
is
ea
se
 C
on
-
tr
ol
, a
nd
 R
es
ea
rc
h;
 
M
in
is
tr
y 
of
 H
ea
lth
 
an
d 
S
oc
ia
l W
el
fa
re
E
th
io
pi
an
 P
ub
lic
 H
ea
lth
 In
st
i-
tu
te
; M
in
is
tr
y 
of
 H
ea
th
N
at
io
na
l P
ub
lic
 H
ea
lth
 
A
ge
nc
y,
 c
ur
re
nt
ly
 u
nd
er
 
de
ve
lo
pm
en
t;
 S
ie
rr
a 
Le
on
e 
M
in
is
tr
y 
of
 H
ea
lth
 a
nd
 
S
an
ita
tio
n
Pr
im
ar
y 
re
se
ar
ch
 
pa
rt
ne
r(
s)
M
an
hi
ça
 H
ea
lth
 R
es
ea
rc
h 
C
en
tr
e;
 B
ar
ce
lo
na
 In
st
itu
te
 
fo
r 
G
lo
ba
l H
ea
lth
 (I
S
G
lo
ba
l)
U
ni
ve
rs
ity
 o
f W
itw
a-
te
rs
ra
nd
; M
ed
ic
al
 
R
es
ea
rc
h 
C
ou
nc
il:
 
R
M
P
R
U
C
en
te
r 
fo
r V
ac
ci
ne
 
D
ev
el
op
m
en
t,
 U
ni
-
ve
rs
ity
 o
f 
M
ar
yl
an
d,
 
B
al
tim
or
e
C
D
C
 K
en
ya
; K
is
um
u 
C
ou
nt
y 
D
ep
ar
t-
m
en
t 
of
 H
ea
lth
; 
K
E
M
R
I
ic
dd
r,b
; B
an
ga
ba
nd
hu
 
S
he
ik
h 
M
uj
ib
 M
ed
-
ic
al
 U
ni
ve
rs
ity
 
H
ar
am
ay
a 
U
ni
ve
rs
ity
; L
on
do
n 
S
ch
oo
l o
f 
H
yg
ie
ne
 a
nd
 
Tr
op
ic
al
 M
ed
ic
in
e 
C
D
C
–S
ie
rr
a 
Le
on
e;
 IC
A
P
 
C
ol
um
bi
a 
U
ni
ve
rs
ity
; F
oc
us
 
10
00
; W
or
ld
 H
op
e 
In
te
r-
na
tio
na
l
A
bb
re
vi
at
io
ns
: C
D
C
, C
en
te
rs
 f
or
 D
is
ea
se
 C
on
tr
ol
 a
nd
 P
re
ve
nt
io
n;
 e
st
., 
es
tim
at
ed
; H
D
S
S,
 h
ea
lth
 a
nd
 d
em
og
ra
ph
ic
 s
ur
ve
ill
an
ce
 s
ys
te
m
; I
N
ST
AT
, I
ns
tit
ut
 N
at
io
na
l d
e 
la
 S
ta
tis
tiq
ue
 (N
at
io
na
l I
ns
tit
ut
e 
of
 S
ta
tis
tic
s)
; K
E
M
R
I, 
Ke
ny
a 
M
ed
ic
al
 R
es
ea
rc
h 
In
st
itu
te
; 
N
IC
D
, N
at
io
na
l I
ns
tit
ut
e 
fo
r 
C
om
m
un
ic
ab
le
 D
is
ea
se
s;
 R
M
P
R
U
, R
es
pi
ra
to
ry
 a
nd
 M
en
in
ge
al
 P
at
ho
ge
ns
 R
es
ea
rc
h 
U
ni
t.
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/69/Supplem
ent_4/S262/5584386 by guest on 23 O
ctober 2019
S266 • cid 2019:69 (Suppl 4) • Salzberg et al
estimates the size and structure of a population by recording 
all births, deaths, and in- and out-migration episodes within 
a defined area. This is usually achieved through an initial 
census and intermittent reenumeration rounds 1–4 times 
per year. This information on key population indicators and 
characteristics, including fertility, mortality, and migration 
rates, also provides the total death count in the population 
to determine the level of ascertainment of deaths within the 
catchment area and explore biases in ascertainment. HDSS 
platforms vary in maturity throughout the network (Table 
1) [37]. Several sites began surveillance with limited or no 
HDSS infrastructure, but these systems are being developed 
as part of the CHAMPS surveillance model. For sites with an 
existing HDSS, surveillance systems are being reviewed and 
strengthened (when necessary) to provide reliable denomin-
ators for rate calculations.
All sites have received approval from appropriate ethics re-
view committees to conduct CHAMPS mortality surveillance. 
The CHAMPS Program Office (PO), based at Emory University, 
has received approval from the Emory University Institutional 
Review Board (IRB). In addition, since the initiation of 
CHAMPS, a team of ethicists from the Emory Center for Ethics 
conducts ongoing review of program practices and policies.
Death Identification and Tracking
The CHAMPS identifier (ID) system accommodates surveil-
lance at site and subsite levels of resolution. Reported deaths 
are issued a report ID to facilitate the tracking and linkage of 
limited data on reported deaths that may not ultimately get en-
rolled. Duplicate notifications are indicated as such in the da-
tabase. Enrolled deaths and mothers with indicated consent 
for maternal abstraction are issued a unique CHAMPS ID; for 
a mother, the CHAMPS ID is associated with the pregnancy 
event related to the deceased child. Therefore, in the case of de-
ceased twins, each twin is issued a unique CHAMPS ID and 
the mother is issued a single Pregnancy CHAMPS ID to asso-
ciate the twins to a single pregnancy event. The mother’s in-
formation is also entered into a maternal registry that links all 
issued Pregnancy CHAMPS IDs. This event-based ID system 
allows the CHAMPS Network to link a single woman to mul-
tiple deceased children over time or link a child to different 
events throughout a lifetime, facilitating the addition of fu-
ture research modules onto the CHAMPS platform. A unique 
MITS specimen collection kit ID is assigned to each MITS that 
is performed; each kit contains prelabeled collection containers 
with barcoded specimen ID labels along with labels for extra 
specimens. The specimen ID number is a combination of the 
specimen kit ID and a component ID that identifies the type of 
specimen collected. The linkage of CHAMPS ID to specimen 
kit ID enables the linking of any laboratory result to a specific 
MITS death.
Mortality Surveillance and Death Notification
Each site has developed mortality surveillance and death notifi-
cation procedures tailored to the needs of their catchment area 
and informed by SBS research, considering site capacity, cultural 
and religious norms and concerns, and geography (Tables 1–3) 
[35, 36]. See Table 4 for examples of how 2 sites are using a call 
center to receive and process death notifications. While some 
level of procedural variation prior to enrollment is supported, 
the PO has developed network-wide data quality and moni-
toring procedures to safeguard essential data elements collected 
upon notification and eligibility screening that may influence 
cause of death determination or are used in aggregate analyses 
(ie, basic demographics and details around the death). This ap-
proach allows sites to conduct surveillance in a contextually 
appropriate manner while also promoting network-wide stand-
ardization of key elements. While some sites have implemented 
both community and health facility–based notification systems, 
others have started notification activities first in a facility setting 
before implementing notification in the community (Table 3).
To identify deaths occurring outside of health facilities, sites 
use a variety of community notification channels to enhance 
ongoing HDSS rounds (Table 3). Community reporters may be 
provided a cell phone and/or airtime to enable them to notify 
study staff of potentially eligible deaths in real time via short 
messaging service (text messaging) or phone calls. When ap-
plicable, efforts are made to ensure that community-based re-
porting is integrated into the site’s existing vital registration 
system, for example, by referring all deaths identified in the 
community to a health center to obtain a death certificate prior 
to enrollment. CHAMPS actively monitors timeliness, com-
pleteness, and representativeness of death notifications from 
facilities and the community through standardized metrics and 
data dashboards with the intent of improving representativeness 
over time. For instance, through monitoring death notifications 
stratified by age group, MITS eligibility, and location of death, 
the Mali site identified that a majority of notified stillbirths were 
already buried at the time of notification, making them inel-
igible for MITS. A few of these stillbirths were delivered in a 
health facility with a round-the-clock surveillance team. Based 
on this information, staff met with midwives and pediatricians 
to reintroduce CHAMPS, emphasize the importance of com-
plete and timely reporting of stillbirths and under-5 deaths, 
and reinforce that midwives and other health facility personnel 
would not be blamed for stillbirths. The site experienced a sub-
sequent increase in timely reporting of stillbirths in the fol-
lowing months.
Mortality Surveillance Data Collection
Upon the notification of a death, surveillance teams collect 
basic information to identify duplicate death notifications and 
to assess eligibility (ie, dates of birth and death, time of death, 
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residency within the catchment area). All information is con-
firmed with the family prior to enrollment.
Enrollment Procedures
For deaths identified within the MITS eligibility timeframe 
(within 24-36 hours of death  or the body has been refrigerated), 
a consenting team is dispatched to the family as soon as possible 
to confirm eligibility. The consenting team is comprised of a 
health worker and staff trained to provide appropriate support 
and/or counseling to parents or family members. Before data 
are collected, a family member or guardian must give consent 
to participate in data collection. Consent procedures have been 
adapted at each site based on local SBS data [36].
ENROLLED DEATH DATA COLLECTION
MITS Procedure
After enrollment, the body is transported to a designated MITS 
procedure room within a local facility, and a series of tissue (ie, 
brain, both lungs, liver, bone marrow, heart) and nontissue spe-
cimens (ie, blood, cerebrospinal fluid, stool via rectal swabs, 
and respiratory secretions via nasopharyngeal/oropharyngeal 
swabs) are collected [38]. For stillbirths and neonatal deaths, 
specimens from the placenta, membranes, and umbilical cord 
are also collected, when available. If deemed culturally appro-
priate, a family member or designee may attend the MITS pro-
cedure if desired (Table 3). Following the completion of the 
procedure, which typically takes 1 hour to complete, the body is 
transported back to a nearby location as requested by the family.
Child and Maternal Clinical Data Abstraction
Available clinical information pertaining to the deceased child 
as well as relevant maternal health information for a subset of 
deaths is abstracted for all enrolled deaths (MITS and non-MITS) 
(Table 5). The completeness of the data available varies greatly 
by site. Clinical records may be obtained from all levels of health 
facilities consulted during the course of the terminal illness/event 
or antenatal care clinics, or may be held by family members.
Clinical information on the delivery and maternal health 
is abstracted for all stillbirths or deaths among infants aged 
<1  year. It is also abstracted for deaths among children aged 
1  year or older if the mother experienced complications or 
Table 2. Selected Health Characteristics of Child Health and Mortality Prevention Surveillance Sites
Characteristic
Mozam-
bique
South  
Africa Mali Kenya Bangladesh Ethiopia Sierra Leone
Mortality data at the time of site 
selectiona
       
 U5MR (per 1000 live births) 71 56 123 76.6 (Siaya) and  
79 (Kisumu)
50 (est.) (Baliakandi);  
unknown (Faridpur)
81.9 (Kersa);  
22 (Harar)
156 
 IMR (per 1000 live births) 40.6 40 78 54 41 (Baliakandi);  
unknown (Faridpur)
45 (Kersa);  
11 (Harar)
92
 NMR (per 1000 live births) 15.6 21 40 39 30 (Baliakandi);  
unknown (Faridpur)
26.2 (Kersa);  
4.1 (Harar)
39
 SBR (per 1000 third-trimester  
pregnancies)
Unknown 23 28 Unknown 22 (Baliakandi);  
unknown (Faridpur)
15.7 (Kersa);  
4 (Harar)
24.8 per 1000 live 
birthsb
 MMR (per 100 000 live births) 208 310 550 495 Unknown 365 1360c; 695.7d
HIV
 Country HIV prevalence,  
age 15–49, % (year)
13.2 (2015) 18.9 (2017) 1.2 (2017)e 21 (Siaya, 2018);  
16.3 (Kisumu, 2018)
<1 (2011) 1.1 (2016) 1.7 (2018)
 Site HIV prevalence, age 15–49,  
% (year)
39.7 (2012) 10 (est.) Unknown Unknown Unknown Unknown Unknown
 HIV prevalence in women of  
reproductive age, % (year)
30 29 1.6 (2017)e 22.4 (Siaya, 2018);  
17.4 (Kisumu, 2018)f
Unknown Unknown Unknown
 Vertical mother-to-child  
transmission rate, %
5 1 Unknowng Unknown Unknown Unknown 12.7
Malaria
 Endemic malaria Yes No Yes Yes No No Yes
Abbreviations: est., estimated; HIV, human immunodeficiency virus; IMR, infant mortality rate; MMR, maternal mortality rate; NMR, neonatal mortality rate; SBR, stillbirth rate per 1000 
births, unless otherwise indicated; U5MR, under-5 mortality rate.
aAll data are from the point of Child Health and Mortality Prevention Surveillance (CHAMPS) site selection (as reported by the site) in 2015 unless otherwise indicated.
bGBD 2016 Mortality Collaborators. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global 
Burden of Disease Study 2016. Lancet 2017; 390:1084–150.
cWorld Health Organization. Trends in maternal mortality: 1990 to 2015. Available at: https://www.who.int/reproductivehealth/publications/.../maternal-mortality-2015/en/.
dGlobal Burden of Disease Study. Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 
388:1775–812.
eJoint United Nations Programme on HIV/AIDS (UNAIDS). 2017 country factsheets, Mali. Available at: http://www.unaids.org/en/regionscountries/countries/mali.
fRate from Jaramogi Oginga Odinga Teaching and Referral Hospital in Kisumu, Kenya.
gBased on UNAIDS 2017 country factsheet for Mali, 31% of pregnant women living with HIV received antiretroviral therapy for the prevention of vertical transmission.
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health problems during the pregnancy, labor, birth, or imme-
diate postpartum period of the child in question.
Verbal Autopsy
For all enrolled deaths, consent is requested to conduct a VA 
interview with a parent, other family member, or caregiver 
close to the child. This standardized interview, ideally con-
ducted 2–4 weeks after the death, is intended to elucidate symp-
toms and signs related to the most common causes of death. 
Trained interviewers administer the WHO 2016 VA question-
naire, adapted to capture CHAMPS and HDSS identifiers and 
modified to include content enhancements, skip logic, and unit 
of measurement corrections (see Supplementary Materials). 
Additionally, CHAMPS developed a software application to re-
ceive and validate multiple VA versions in the field; some sites 
initially used the WHO 2012 VA instrument [39], and subse-
quently transitioned to the WHO 2016 VA.
Verbal autopsy data are analyzed by automated diagnostic 
algorithms, such as openVA [40], for statistical assignment of 
probable causes of death and for assessing ways to improve VA 
procedures and interpretations when compared to DeCoDe-
generated cause of death determinations for MITS deaths. The 
automated VA conclusions are not provided to the DeCoDe 
panel, which instead receives the individual VA responses.
CAUSE OF DEATH DETERMINATION PROCESS
The DeCoDe panel comprises at least 1 of each of the following: 
clinician (eg, pediatricians, neonatologists, and obstetricians), 
pathologist, epidemiologist, and microbiologist. Panelists re-
ceive all available information from linked maternal data, child 
clinical data, individual demographic data, VA, microbiology, 
molecular testing, clinical diagnostics (human immunode-
ficiency virus [HIV], tuberculosis, malaria), photographs of 
the deceased from the MITS procedure, and histopathology 
Table 4. Call-Center Notification Systems
Faridpur/Baliakandi, Bangladesh Bombali Shebora/Bombali Siari, Sierra Leone
The Bangladesh CHAMPS site developed a toll-free physician call center, 
partnering with MIAKI Media Ltd, to increase death reporting and also pro-
vide a service to the community. Through widely distributed health informa-
tion materials, community members are instructed to call the center if they 
experience complications with pregnancy, child illness, or a medical emer-
gency or would like newborn health advice. In case of illness, physicians 
discuss symptoms with callers to ascertain if there are any danger signs that 
require immediate referral to 1 of 6 designated health facilities. Community 
members are also instructed to call the center for reporting of births and 
child deaths. If a child mortality or stillbirth event is reported, relevant infor-
mation is documented and communicated to the CHAMPS team. In addition 
to providing a platform for community death reporting, this system also 
enhances community access to physician consultation and improves the 
community’s abilities to make informed healthcare-seeking decisions.
The Sierra Leone CHAMPS site utilizes an existing toll-free call center to 
increase community-wide death reporting. The national emergency call 
system (known by its phone number, 117) was established in 2012 as part of 
a support system to improve maternal and child health and scaled up during 
the 2014–2016 Ebola outbreak for reporting all deaths and suspected cases 
of Ebola. Health providers and community members are instructed to call 
117 to report all deaths. While overall reporting of deaths to 117 dropped 
sharply following the end of the Ebola epidemic, CHAMPS facility and com-
munity reporters have been trained to report child deaths and stillbirths to 
the call center, thereby increasing the system’s utilization and strengthening 
its utility. Additionally, the CHAMPS sociol-behavioral science team has con-
ducted extensive community engagement to encourage widespread com-
munity use of the call center, addressing stigmatization that exists around 
the call center as a result of the Ebola epidemic. As a result of such activity, 
the CHAMPS catchment area Bombali District has the highest numbers 
of notified deaths to 117 in the country. When a child mortality or stillbirth 
event from within the CHAMPS catchment area is reported, relevant infor-
mation is documented and communicated to the CHAMPS team. As the 
current civil registration and vital statistics data collection is paper-based, 
the 117 system provides an opportunity for creating an electronic reporting 
of deaths for civil registration and mortality surveillance programs.
Abbreviations: CHAMPS, Child Health and Mortality Prevention Surveillance.
Table 5. Child and Maternal Health Information Abstracted for Minimally 
Invasive Tissue Sampling (MITS) and Non-MITS Cases
Form Data Category
Child  
abstraction
Basic case information
 Recent hospital encounters and hospitalization leading to 
death
 Physical examination
 Past medical history
 Birth history
 Immunization records
 Growth chart
 Child and maternal HIV and TB information
 Diagnostic information
 Clinical summarya
Maternal 
abstractionb
Maternal demographic information
 Antenatal clinic history
 Pregnancy, labor, and delivery
 Placenta and cord description
 Maternal laboratory testing and treatments
 Maternal medications
 Maternal transfusions
 Information of previous pregnancies and pregnancy  
outcomes
 Perinatal outcome and basic characteristics of the enrolled 
deceased child
 Maternal death information (if applicable)
Abbreviations: HIV, human immunodeficiency virus; TB, tuberculosis.
aClinical summary may be transcribed directly from patient records (if available) or may be 
composed by clinically experienced abstractors based upon available clinical data.
bMaternal records related to the deceased enrolled child are abstracted.
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findings in the form of a DeCoDe packet and assign underlying, 
antemortem, and immediate (and other contributing) causes of 
death [34]. A unique version identifier and date/time stamp is 
created each time a DeCoDe packet is created, enabling regen-
eration of the packet if new information is added or a new panel 
reviews and provides another set of cause of death results.
COMMUNICATING RESULTS
For deaths with a MITS performed, sites communicate this 
cause(s) of death to family members. The objective is to deliver 
results within 4 months of the death; however, a variety of chal-
lenges may delay this process. For instance, urban communities 
are highly transient and therefore, families are difficult to trace. 
Additionally, some DeCoDe panel assessments are delayed by 
the complexity of the necessary analyses.
Site staff communicate DeCoDe results to parent/guardians 
using understandable language and visual aids when appro-
priate. Findings may include negative test results as appropriate 
(such as indicating that the child did not have malaria or HIV); 
in some cases, the cause of death remains undetermined. If 
measures are identified that could have potentially prevented 
the child’s death (eg, timing of care seeking, danger signs), these 
are discussed with the family. Several sites conduct either fol-
low-up interviews with participating families or observe the de-
livery of cause of death information to improve the process of 
delivering results to families. Diagnoses (such as tuberculosis 
or HIV) with clear public health implications or statutory re-
porting requirements are provided to local public health staff 
for follow-up. In some cases, it is necessary to communicate 
with families and other relevant parties before the DeCoDe re-
sults are available, based on a clinically relevant laboratory result 
(ie, positive for syphilis, HIV, tuberculosis, meningococcus, or 
cholera). In these cases, the site notifies the local public health 
authority, based on local reporting requirements, as well as 
notifies the family and treating clinician/facility. Additionally, 
local law enforcement may be notified in cases where child mal-
treatment is identified.
Findings are also shared with communities, local govern-
ment, public health authorities, and facilities to guide public 
health action to prevent future child deaths and illness (Table 
6). To facilitate this process, the International Association of 
National Public Health Institutes works with national and 
subnational public health authorities associated with the sites to 
ensure they have the skills and tools necessary to interpret and 
use CHAMPS data and integrate it with other sources of child 
mortality data with the objective of informing public health 
guidelines, resource allocation, policies, programs, communi-
cation strategies, and interventions.
TRAINING
Site mortality surveillance staff are trained according to their 
responsibilities. The PO developed training modules that are 
adapted according to site-specific procedures and require-
ments. Training modules include death identification proced-
ures, assignment of CHAMPS IDs, linkage and de-duplication 
of data, death notification, enrollment and consent, loss and 
grief training, compassionate interview skills, general biosafety 
procedures (including universal precautions and use of personal 
Table 6. Child Health and Mortality Prevention Surveillance as a Mechanism for Data to Action
Soweto, South Africa Manyatta, Kisumu County, Kenya
In South Africa, CHAMPS mortality surveillance was first launched in Chris 
Hani Baragwanath Hospital, a central hospital in Soweto. Based on initial 
DeCoDe data from these hospital-based cases, hospital-acquired infections 
were identified as a leading cause of neonatal mortality in that site. As 
a result, the South Africa CHAMPS team, in partnership with the United 
States CDC, led a critical appraisal of current facility infection prevention 
and control practices and subsequently, received a grant from the Bill & 
Melinda Gates Foundation to develop a package of interventions to mitigate 
against the risk of hospital infections. Additionally, based on the initial round 
of DeCoDe data, the site identified that approximately 20% of stillbirths 
in the South Africa site may be due to invasive bacterial infection of the 
fetus. This has led to increased sensitivity of facility-based obstetricians to 
the value in stillbirth investigation and has invigorated a research agenda 
aimed at addressing the burden of stillbirths in South Africa, a significant, 
yet largely ignored population. Through the review of data and evaluation of 
potential causes and mitigation factors, the CHAMPS South Africa site is 
ensuring that CHAMPS data will not only contribute toward a better under-
standing of child mortality but will also actively improve the overall health of 
its population.
The Kenya CHAMPS site, in collaboration with the Kisumu County MOH, 
recently established an HDSS system in Manyatta aimed at strengthening 
existing MOH surveillance by systematizing and improving documenta-
tion. Establishment of the HDSS included mapping of households and 
enumerating residents through a baseline survey that established a unique 
identifier for each individual. According to the MOH, the area covered by 
each CHV should include between 100 and 120 households. Mapping 
demonstrated that areas allocated to CHVs had significantly more house-
holds than previously thought; some had from 250 to 650 households and 
one CHV village had >800 households. The implications of the underesti-
mation mean that CHVs only visited the first 100–120 households in their 
coverage area and stopped there, returning to the same households on 
subsequent visits. This impacts intervention planning since only a frac-
tion of the population would potentially be reached. As an example, bed 
nets were distributed to households in Manyatta, yet many households 
reported not receiving one due to the underestimation of the need. Based 
on the information gathered through the HDSS mapping and enumeration, 
the coverage area allocated to each CHV was examined by Kisumu County 
MOH. The process of realigning the areas allocated to CHVs to conform 
to a maximum of 120 households and recruitment of additional CHVs is 
ongoing. The mapping and enumeration will allow CHAMPS to have an 
accurate denominator for calculating rates of under-5 mortality and also 
provide adequate coverage by CHVs for all the households.
Abbreviations: CDC, Centers for Disease Control and Prevention; CHAMPS, Child Health and Mortality Prevention Surveillance; CHV, community health volunteer; DeCoDe, Determination 
of Causes of Death; HDSS, health and demographic surveillance system; MOH, Ministry of Health.
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protective equipment), confidentiality and ethics, VA proced-
ures, and abstraction procedures. Additionally, in collaboration 
with sites and the PO, ISGlobal and the Centers for Disease 
Control and Prevention conduct trainings for MITS specimen 
collection, histopathology, telepathology and TaqMan Array 
Card assays [38, 41]. Sites conduct training evaluations and re-
train as necessary.
STATISTICAL ANALYSIS AND DATA ACCESSIBILITY
Sites aim to enumerate and approach families of all eligible 
deaths for consent, whether MITS or non-MITS. The number 
of deaths with a MITS performed is determined by community 
acceptability, birth cohort and under-5 population, and number 
of deaths rather than theoretical considerations or power calcu-
lations. As a result of both the complexities involved with con-
ducting community-based mortality surveillance and consent 
for MITS, the majority of enrolled deaths (particularly MITS 
deaths) during the initial phase of CHAMPS were identified 
through health facilities. Therefore, initial results may not be 
representative of the catchment population, as many deaths 
occur at home and may have different causes of death than 
facility-based deaths. As surveillance systems mature and a 
greater proportion of deaths occurring outside of facilities un-
dergo MITS, the results will become more representative of the 
study populations.
CHAMPS will describe relative contributions to under-5 
mortality of conditions and specific etiologies (eg, diarrheal 
disease, respiratory illness, febrile illness and associated patho-
gens, as well as noninfectious diseases) stratified by age group 
(eg, stillbirth and neonatal mortality) by site and across sites. 
Data collected will allow for the consideration of a variety of 
contributors to death, whenever available, including levels of 
illness severity, delays in accessing care, quality of care, general 
healthcare access, host factors (including malnutrition and in-
heritable diseases, like hemoglobinopathies), and comorbid 
conditions. As data accumulate, the network will extrapolate 
to estimate regional burden of specific causes of death. In ad-
dition, CHAMPS data are accessible to the scientific, clinical, 
and public health communities through its website (www.
champshealth.org).
DISCUSSION
CHAMPS is an ambitious, longitudinal, mortality surveil-
lance project that will determine the causes of child mortality 
in 7 sites in sub-Saharan Africa and South Asia, regions with 
high child mortality and limited capacity to generate specific 
cause of death information. From program inception, sites 
have collaborated closely with local government and public 
health officials to ensure that data collected are available 
to influence recommendations, policies, and interventions 
(Table 6). Additionally, aggregate data are publicly accessible 
via the CHAMPS website, with more detailed data available 
upon request and IRB approval (as required). As mortality 
detection systems are strengthened and sites capture propor-
tionately more of the deaths that occur within their catch-
ment populations, the scope for bias will decrease and the 
results will be more representative. Additionally, the accumu-
lation of deaths with a DeCoDe panel cause of death deter-
mination (projected 10  000 by 2025)  will allow for a better 
understanding and contextualization of laboratory findings 
(eg, the role of coinfections in mortality, relative importance 
of certain pathogens in the mortality chain) and improved 
interpretation of VA results.
While CHAMPS has the potential to contribute significantly 
to the understanding of all-cause child mortality, common chal-
lenges arise from conducting multisite mortality surveillance. 
Although sites aim to enumerate all eligible under-5 deaths and 
stillbirths within their catchment area, many site HDSS systems 
do not yet have a precise way of identifying all eligible deaths in 
the catchment area and therefore, defining complete ascertain-
ment is challenging. As sites continue to invest in the develop-
ment and strengthening of their HDSS systems (when needed) 
and as enrolled deaths accumulate, reliability and confidence in 
site-level population denominators will increase and sites will 
have more accurate measurements of their success in complete 
mortality detection.
A variety of challenges limit the network’s current ability to 
extrapolate and generalize results. The representativeness of the 
data is limited without a full understanding of the deaths that 
may be missed by a surveillance system, particularly if those 
deaths are biased for particular factors (ie, access to healthcare, 
socioeconomic factors, demographic characteristics, criminal/
legal potential that prohibits inclusion). Sites currently cap-
ture a larger proportion of deaths that occur within facilities 
than those that occur within the community. There is limited 
generalizability to areas outside of the catchment area, as the 
catchment area may not be representative of the rest of the host 
country or other similar areas. CHAMPS is developing methods 
based on Bayesian techniques to extrapolate from such poten-
tially nonrepresentative samples, using data collected from the 
underlying population, such as age, sex, location, and season of 
death (to be described in a future publication).
Additionally, the MITS procedure has limited direct utility 
in determining cause of death from certain causes, including 
trauma, noninfectious causes of death such as congenital heart 
disease, occult congenital abnormalities, and genetic disorders 
not easily detectable by targeted specimen collection or pho-
tography. Localized organ lesions may not be appropriately 
sampled with fine needles through the “blind” biopsy method-
ology employed in the MITS procedure (ie, the needle did not 
enter the area of the infection). However, the MITS procedure 
has proven to be a widely acceptable method of postmortem 
examination in areas where full autopsies are not feasible and 
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compared with CDA, the procedure has been shown to be 
highly accurate and sensitive [14, 23, 24, 29].
Routinely collecting specimens from bodies of dead chil-
dren requires understanding of cultural, familial, and religious 
beliefs around death. Staff must be sensitive to the shock and 
grief of a family in response to the child’s death. In anticipation 
of these challenges, site SBS teams conduct activities to better 
understand the feasibility of CHAMPS procedures, beginning 
their work prior to launching mortality surveillance and contin-
uing during program implementation [36]. Site community en-
gagement teams work with local communities and stakeholders 
to address misconceptions about CHAMPS, and MITS in par-
ticular, in a timely manner, to increase and sustain the accepta-
bility of MITS [35].
These challenges and limitations also provide opportunities for 
growth. SBS activities have been a key component to each site’s 
project implementation, with community engagement and for-
mative research impacting how data are collected and how staff 
interact with community members. For instance, in Kenya, the 
SBS team identified that black cars, often used to transport the 
dead, were perceived by the community as an omen of death. This 
led to the site modifying their approach to body transportation 
and no longer using black cars to transport a body. In Bangladesh, 
consent procedures were adapted to engage the broader family 
network (rather than just the mother or father) based on SBS as-
sessments that revealed that consent rates rose when the broader 
family could decide together whether to participate in CHAMPS. 
The incorporation of SBS findings into project implementation 
helps promotes community ownership over the CHAMPS pro-
gram and ultimately can lead to greater participation and poten-
tial to use generated data for local and regional action. Many sites 
have formed community advisory boards that provide insight into 
how activities should align with community priorities. Local pro-
ject champions help increase acceptance of the program as well as 
promote a better understanding of the program’s ultimate goals 
within their communities [35]. Additionally, the integration of 
family feedback and follow-up into the project will improve our 
understanding of the impact that data have on individual family 
members and surrounding communities. Finally, the wide net-
work of sites has allowed for the ultimate improvement of cross-
network tools (eg, 2016 WHO VA) and procedures.
Despite known and potential limitations and the expected chal-
lenges, by 20 June 2019, 1276 MITS were conducted from across 
the 7 CHAMPS sites and DeCoDe panels have met and completed 
cause of death determinations for 860 of these deaths [42]. Despite 
limited numbers, these determinations have already provided in-
sights on contributions of key pathogens (eg, respiratory syncytial 
virus, malaria, Streptococcus pneumoniae, group B Streptococcus, 
malnutrition, preterm birth, and congenital abnormalities) within 
the causal chain of child mortality. As enrolled deaths accumulate 
and confidence in site-level population denominators increases 
through strengthening the HDSS [37], CHAMPS will provide 
specificity for how specific causes of death contribute to mortality 
burden. Data generated from CHAMPS will ultimately inform 
potential strategies to achieve the United Nations Sustainable 
Development Goal 3.2 to reduce the high stillbirth and under-5 
child mortality seen in Africa and South Asia.
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